Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Am J Med Genet A. 2017 Sep 25;176(5):1099–1107. doi: 10.1002/ajmg.a.38457

Table V.

Changes in the Aberrant Behavior Checklist – Community (ABC) raw scores after one year of treatment with levodopa or placebo, and the relative difference in the changes between these two groups. A positive “difference in gains” suggests that either the gain (i.e., worsening) in that behavior was greater in the levodopa group than in the control group, or the reduction (i.e., improvement) in that behavior was less in the levodopa group compared to the control group.

Aberrant Behavior
Checklist Raw
Score: Mean ± SD
Levodopa (n=29) Placebo (n=26) Difference
in Gains
(Levodopa -
Placebo)
Difference in Gains (Generalized
Estimating Equation)
Initial 1-year Gain in
1 year
Initial 1-year Gain in
1 year
95% C.I. p value
Irritability 9.1 (± 9.3) 7.3 (± 8.0) −1.8 4.8 (± 6.0) 6.6 (± 7.1) 1.8 −3.6 (−6.85, 0.16) 0.06
Lethargy 4.7 (± 4.6) 4.5 (± 3.9) −0.3 2.7 (± 3.3) 5.2 (± 8.4) 2.5 −2.8 (−6.37, 0.76) 0.12
Stereotypy 5.1 (± 3.7) 3.5 (± 3.7) −1.6 3.0 (± 3.6) 3.6 (± 3.9) 0.7 −2.2 (−3.93, −0.33) 0.02
Hyperactivity 19.5 (± 12.2) 18.2 (± 9.9) −1.3 15.5 (± 10.8) 17.0 (± 10.4) 1.5 −2.8 (−7.74, 1.66) 0.20